Is there a place for mucolytics in the treatment of chronic obstructive pulmonary disease?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the modern concept of the pathogenesis of hyperproduction of bronchial mucus in chronic obstructive pulmonary disease. The symptoms of COPD are described: cough, sputum expectoration and episodic exacerbations, most characteristic of the bronchitis phenotype. An assessment of the close relationship of bronchial mucus overproduction, mucostasis, the development of exacerbations (including infectious ones) and disease progression is given. The modern classification of mucoactive drugs is presented. The effectiveness of mucoactive drugs in chronic obstructive pulmonary disease (antioxidant and/or mucolytic action) is discussed. Acetylcysteine, an active mucolytic and powerful antioxidant, attracts special attention.

Full Text

Restricted Access

About the authors

I. L Klyachkina

Russian Medical Academy of Continuous Professional Education

Email: formozailk2012@yandex.ru
PhD, Associate Professor, Department of Pulmonology

References

  1. Button B, Goodell H.P, Atieh E., et al. Roles of mucus adhesion and cohesion in cough clearance. Proc Natl Acad Sci USA. 2018;115:12501-506. Doi: 10.1073/ pnas.1811787115.
  2. Okuda K., Chen G., Subramani D.B., et al. Localization of secretory mucins MUC5AC and MUC5B in normal/ healthy human airways. Am J Respir Crit Care. 2019;199(6):715-27. doi: 10.1164/rccm.201804-Q734OC.
  3. Widdicombe J.H., Wine J.J. Airway gland structure and function. Physiol Rev 2015;95:1241-319. doi: 10.1152/physrev.00039.2014.
  4. Henderson A.G., Ehre C., Button B., et al. Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. J Clin Invest. 2014;124:3047-60. doi: 10.1172/JCI73469.
  5. Kesimer M., Ford A.A., Ceppe A., et al. Airway mucin concentration as a marker of chronic bronchitis. N Engl J Med. 2017;377:911-22. Doi: 10.1056/ NEJMoa1701632.
  6. Button B., Cai L.H., Ehre C., et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science. 2012;337:937-41. doi: 10.1126/sdence.1223012.
  7. Boucher R.C. Human airway ion transport: part one. Am J Respir Crit Care Med. 1994;150:271-81. doi: 10.1164/ajrccm.150.1.8025763.
  8. Fahy J.V, Dickey B.F. Airway mucus function and dysfunction. N Engl J Med. 2010;363:2233-247. doi: 10.1056/NEJMra0910061.
  9. Button B, Okada S.F, Frederick C.B., et al. Mechanosensitive ATP release maintains proper mucus hydration of airways. Sci Signal. 2013;6:ra46-ra46. doi: 10.1126/scisignal.2003755.
  10. Richard C, Boucher, M.D. Muco-Obstructive Lung Diseases N Engl J Med. 2019;380:1941-53. doi: 10.1056/NEJMra1813799.
  11. Leith D.E. Cough. Phys Ther. 1968;48:439-47. doi: 10.1093/ptj/48.5.439
  12. Cole A.M., Liao H.I., Stuchlik O., et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 2002;169:6985-91. Doi: https://doi.org/10.4049/jimmunol. 169.12.6985.
  13. Livraghi-Butrico A., Grubb B.R., Wilkinson K.J., et al. Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease. Mucosal Immunol. 2017;10:395-407.
  14. Sethi S., Maloney J., Grove L., et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:991-98.
  15. Lee A.L., Button B.M., Denehy L, et al. Proximal and distal gastro-oesophageal reflux in chronic obstructive pulmonary disease and bronchiectasis. Respirology. 2014;19:211-17. doi: 10.1111/resp.12182.
  16. Segal L.N., Clemente J.C., Tsay J.C., et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat Microbiol. 2016;1:16031-31. Doi: 10.1038/ nmicrobiol.2016.31.
  17. Boucher R.C. On the pathogenesis of acute exacerbations of mucoobstructive lung diseases. Ann Am Thorac Soc. 2015;12:S160-S163. Doi: 10.1513/ AnnalsATS.201507-460AW.
  18. Han M.K, Agusti A., Calverley PM., et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182:598-604. doi: 10.1164/rccm.200912-1843CC.
  19. Barnes PJ., D.Sc. Chronic Obstructive Pulmonary Disease. N Engl J Med. 2000;343:269-80.
  20. Hogg J.C., Pare PD., Hackett T.L. The contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease. Physiol Rev. 2017;97:529-52. Doi: 10.1152/ physrev.00025.2015.
  21. Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007, 52:1176-93.
  22. Burgel PR., Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135:975-82. Doi: 10.1378/ chest.08-2062.
  23. Speizer F.E., Fay M.E., Dockery D.W., et al. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis. 1989;140(3):49-55. doi: 10.1164/ajrccm/140.3_Pt_2.S49.
  24. Prescott E., Lange P., Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J. 1995;8:1333-38. doi: 10.1183/09031936.95.08081333.
  25. Vestbo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153:1530-35.
  26. Balsamo R., Lanata L., Egan C.G. Mucoactive drugs. Eur Respir Rev. 2010;19(116):127-33. doi: 10.1183/09059180.00003510.
  27. Boman G., Backer U., Larsson S., et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983;64(6): 405-15.
  28. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine:its reaction with hydrogen peroxide and hypochlorous acid. Free Radic Biol Med. 1989;6(6):593-97. doi: 10.1016/0891-5849(89)90066-x.
  29. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. (Based on an April 1998 NHLBI/WHO Workshop) Report. Publication 2701. 2001.
  30. Grassi C., Morandini G.C. A controlled trial of intermit tent oral acetylcysteine in the longterm treatment of chronic bronchitis. Eur J Clin Pharmacol. 1976;9(5-6):393-96. doi: 10.1007/bf00606554.
  31. Hansen N.C., Skriver A., Brorsen Riis L., et al. Orally administered N-acetylcysteine may improve general wellbeing in patients with mild chronic bronchitis. Respir Med. 1994;88(7):531-35. doi: 10.1016/s0954-6111(05)80337-3.
  32. Pela R., Calcagni A.M., Subiaco S., et al. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 1999;66(6):495-500. doi: 10.1159/000029447.
  33. Decramer M., Rutten-van- Molken M., Dekhuijzen P.N.R., et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005;365:1552-60.
  34. Zheng J.P, Wen F.Q., Bai C.X., et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2(3):187-94. Doi: 10.1016/ S2213-2600(13)70286-8.
  35. Miravitlles M., Soler-Catabha J.J., Calle M., et al. Spanish Society of Pulmonology and Thoracic Surgery Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery Arch Bronconeumol. 2012;48(7):247-57. Doi: 10.1016/j. arbres.2012.04.001.
  36. Criner G.J., Bourbeau J., Diekemper R.L., et al. Prevention of acute exacerbations of COPD: American College of ChestPhysiciansandCanadianThoracicSocietyGuideline. Chest. 2015;147(4):895-942. Doi: 10.1378/ chest.14-1676.
  37. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. Available from: http://www.goldcopd.org/

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media